Novavax begins phase three trial for Covid-19 vaccine
Novavax will be the latest company to begin phase three of its vaccine trial. The trial will have up to 30,000 volunteers enrolled across approximately 115 sites in the U.S. and Mexico. CNBC’s \”Squawk on the Street\” crew discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi \n\n» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision\n» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC\n» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic\n\nTurn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.\n\nThe News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast \n \nConnect with CNBC News Online\nGet the latest news: http://www.cnbc.com/\nFollow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC\nFollow CNBC News on Facebook: https://cnb.cx/LikeCNBC\nFollow CNBC News on Twitter: https://cnb.cx/FollowCNBC\nFollow CNBC News on Instagram: https://cnb.cx/InstagramCNBC\n\nhttps://www.cnbc.com/select/best-credit-cards/ \n\n#CNBC\n#CNBCTV
Novavax begins financial trials of its COVID-19 vaccine in the US
Novavax Inc has begun large-scale final trials of its experimental COVID-19 vaccine in the United States, the drug developer said Monday after postponing trials twice due to problems with expanding its manufacturing process..
A US vaccine development company headquartered in Gaithersburg, Maryland, said it will recruit up to 30,000 volunteers at about 115 centers in the US and Mexico, with two-thirds of them getting the vaccine 21 days apart and the rest getting placebo.
Novavax lags behind other manufacturers in the global race to develop vaccines against COVID-19, as vaccines from Pfizer and Moderna are already authorized for emergency use in the US.
But experts said multiple vaccine options would be required to end the coronavirus pandemic, which has killed more than 1.7 million people worldwide..
Novavax has signed supply agreements with several countries and intends to ship 60 million doses to the UK, where late-stage trials are underway. Interim data on test results expected in the first quarter of 2021.
The company is also gearing up to ship 100 million doses to the U.S. by January after receiving $ 1.6 billion to develop and test its potential vaccine..
Novavax is also conducting a fully registered Phase 2b trial in South Africa and a continuation of Phase 1/2 in the US and Australia..
Performance data for these trials may be available early next year.